3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Ovarian Neoplasms
9
Breast Neoplasms
9
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Carcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms, Unknown Primary
2
Neoplasms
2
NSCLC
2
Melanoma
2
Esophageal Neoplasms
2
Adenocarcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled